Induction chemotherapy (IC) docetaxel (T), cisplatin (P), 5-fluorouracil (F) (TPF), or TP followed by concomitant boost radiotherapy (R) with or without cetuximab (E) for functional organ preservation (FOP) of resectable laryngeal and hypopharyngeal cancer (LHSCC): First results of the phase II randomized DeLOS-II study.

Dietz, Andreas; Flentje, Michael; Hagen, Rudolf; Bockmuehl, Ulrike; Koelbl, Oliver; Schilling, V.; Maschmeyer, Georg; Schroeder, Ursula C.; Sittel, Christian; Göerner, Martin; Lenarz, T.; Klußmann, Jens Peter; Guntinas‐Lichius, Orlando; Rudack, Claudia; Reinisch, Sabine; Foerg, Thomas; Westhofen, Martin; Welkoborsky, H.-J.; Eßer, Dirk; Keilholz, Ulrich

doi:10.1200/jco.2014.32.15_suppl.6016

Cited by 8 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A German LP trial [ 54 ] utilized a protocol with three cycles of TPF-ICT (dose according to the TAX 323 trial) → CCRT (concomitant boost RT) with or without cetuximab for 16 weeks (starting with ICT and continuing with RT) in 180 patients. In case of non-response after the first cycle, salvage laryngectomy was performed.…”

Section: Prospective Studies Of T3–t4 Laryngeal Cancermentioning

confidence: 99%

Radiotherapy for locally advanced resectable T3–T4 laryngeal cancer—does laryngeal preservation strategy compromise survival?

Yamazaki

Suzuki

Nakamura

et al. 2017

Journal of Radiation Research

View full text Add to dashboard Cite

With the advancement of chemotherapy, a laryngeal preservation (LP) strategy was explored with the aim of improving maintenance of quality of life. Induction chemotherapy (ICT) following radiotherapy (RT) was considered a viable option because of its high initial response rate without hampering of overall survival (OS). Subsequently, concurrent chemoradiotherapy (CCRT) using CDDP became the standard of care for LP, showing the best LP ratio. For enhancing treatment intensity, ICT with taxan + CDDP + 5-FU (TPF-ICT) followed by RT showed superiority over ICT with CDDP + 5-FU (PF-ICT) followed by RT. Given that almost all randomized controlled trials investigating ICT include not only operable (endpoint, LP) but also inoperable (endpoint, OS) cases, physicians are faced with a dilemma regarding application in daily practice. In addition, increased treatment intensity causes augmentation of adverse events, which might reduce compliance. Thereafter, cetuximab, an effective drug with fewer adverse effects [bioradiotherapy (BRT)], emerged as another option. However, little evidence has confirmed its superiority over RT (or CCRT) in laryngeal cancer subpopulations. In spite of these developments, the OS of patients with laryngeal cancer has not improved for several decades. In fact, several studies indicated a decrease in OS during the 1990s, probably due to overuse of CCRT. Fortunately, the latter was not the case in most institutions. Currently, no other treatment has better OS than surgery. The eligibility criteria for LP and/or surgery largely depend upon the available expertise and experience, which differ from one institution to another. Therefore, a multidisciplinary team is required for the treatment of LP.

show abstract

Section: Prospective Studies Of T3–t4 Laryngeal Cancermentioning

confidence: 99%

Radiotherapy for locally advanced resectable T3–T4 laryngeal cancer—does laryngeal preservation strategy compromise survival?

Yamazaki

Suzuki

Nakamura

et al. 2017

Journal of Radiation Research

View full text Add to dashboard Cite

show abstract

“…A German larynx preservation trial [21] used a protocol with three cycles TPF (dose according to TAX 323) followed by concomitant boost radiotherapy with or without standard dose of cetuximab (E) for 16 weeks (starting with ICT and continues over RT). In case of non-response after the first cycle, the study therapy was terminated and salvage laryngectomy was performed.…”

Section: Studies Comparing Ict To Rctmentioning

confidence: 99%